Infectious disease
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.
The U.S. expansion will recruit up to 30,000 adults over the age of 18 years from a broad range of racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions.
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.
Research published in Lancet Oncology August 24th analyzed that risk by tumor subtype and patient demographics, looking at 1,044 patients from 60 medical centers throughout the UK.
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
On Sunday, U.S. Food and Drug Administration Commissioner Stephen Hahn told the Financial Times that he would potentially fast-track a COVID-19 vaccine before clinical trials are done if it was “appropriate.”
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
One day after Abbott secured Emergency Use Authorization for its $5 coronavirus test, the White House awarded the company a $750 million contract to deliver 150 million Abbott BinaxNOW COVID-19 Ag Card Point of Care (POC) SARS-CoV-2 diagnostic tests.
PRESS RELEASES